Morita Shinya, Nakamaru Yuji, Homma Akihiro, Yasukawa Shinichiro, Hatakeyama Hiromitsu, Sakashita Tomohiro, Kano Satoshi, Fukuda Atsushi, Fukuda Satoshi
Department of Otolaryngology-Head and Neck Surgery, Hokkaido University Graduate School of Medicine, Kita 15, Nishi 7, Kita-ku, Sapporo, Hokkaido, 060-8638, Japan.
Department of Translational Pathology, Hokkaido University Graduate School of Medicine, Sapporo, Japan.
Int J Clin Oncol. 2017 Feb;22(1):181-189. doi: 10.1007/s10147-016-1026-5. Epub 2016 Aug 3.
The aim of this study was to investigate the expression of p53, p16, cyclin D1, epidermal growth factor receptor (EGFR) and Notch1 in temporal bone squamous cell carcinoma (TBSCC) tissue samples by immunohistochemistry (IHC), and to evaluate the association between these biomarkers and clinicopathological features.
We performed a retrospective, single-institution review of 30 TBSCC patients treated with curative intent between April 2006 and March 2015. All tissue samples were obtained from pretreatment biopsy specimens or surgical specimens and using IHC staining.
Ten patients were categorized as T1, seven as T2, five as T3 and eight as T4. Nine patients had clinically positive lymph node metastasis. The positive expression of p53 and EGFR was significantly associated with T classification (P = 0.042 and P = 0.0039). EGFR expression was significantly more frequent in patients with positive lymph node metastasis compared with patients without node involvement (P = 0.017). In the analysis of the association between protein expression by IHC staining and prognosis, the positive expression of EGFR and Notch1 was significantly correlated with poor survival outcomes in TBSCC (P = 0.015 and P = 0.025) CONCLUSION: Overexpression of p53 and EGFR may be valuable biomarkers for identifying individuals at high risk of developing tumors in TBSCC. Furthermore, the positive expression of EGFR was significantly associated with poor survival outcome. Anti-EGFR therapy has potential for use as the treatment modality of choice for advanced-stage TBSCC as well as other head and neck squamous cell carcinomas.
本研究旨在通过免疫组织化学（IHC）研究颞骨鳞状细胞癌（TBSCC）组织样本中p53、p16、细胞周期蛋白D1、表皮生长因子受体（EGFR）和Notch1的表达，并评估这些生物标志物与临床病理特征之间的关联。
我们对2006年4月至2015年3月期间接受根治性治疗的30例TBSCC患者进行了单机构回顾性研究。所有组织样本均取自治疗前活检标本或手术标本，并进行IHC染色。
10例患者分类为T1，7例为T2，5例为T3，8例为T4。9例患者有临床阳性淋巴结转移。p53和EGFR的阳性表达与T分类显著相关（P = 0.042和P = 0.0039）。与无淋巴结转移的患者相比，EGFR表达在有阳性淋巴结转移的患者中显著更频繁（P = 0.017）。在分析IHC染色的蛋白质表达与预后之间的关联时，EGFR和Notch1的阳性表达与TBSCC的不良生存结果显著相关（P = 0.015和P = 0.025）。结论：p53和EGFR的过表达可能是识别TBSCC中发生肿瘤高风险个体的有价值生物标志物。此外，EGFR的阳性表达与不良生存结果显著相关。抗EGFR治疗有潜力作为晚期TBSCC以及其他头颈部鳞状细胞癌的首选治疗方式。
